Drugs / pradefovir
pradefovir
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00230490 | Jun 2005 → May 2007 | chronic hepatitis B virus infection | Bausch Health Americas, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00230503 | Jun 2004 → Dec 2006 | chronic hepatitis B virus infection | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04543565 | Sep 2020 → Oct 2022 | chronic hepatitis B virus infection | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pradefovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00230490 ↗ |
| Known as | Mb06866 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2096895 ↗ |
| Known as | Pradefovir mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2096895 ↗ |
| Known as | PRADEFOVIR MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2096895 ↗ |
| Modality | Small molecule | “Pradefovir is a liver-targeted prodrug of adefovir, a nucleoside/nucleotide analogue with antiviral activity against hepatitis B virus (HBV) DNA polymerase.” PMID 34487151 ↗ Jun 2022 |
| Route | Oral | “oral pradefovir (30, 45, 60, or 75 mg)” PMID 34487151 ↗ Jun 2022 |